Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009

Thursday, September 24, 2009 8:05 AM

Sep. 24, 2009 (Business Wire) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, taking place from Sept. 29 to Oct. 2. The companies will present the latest research findings on BYETTA^® (exenatide) injection and exenatide once weekly. The EASD annual meeting, which brings together more than 14,000 delegates, is the most important platform in Europe for professional exchange in the diabetes field.

“The presentations at EASD continue to reinforce the efficacy and safety of BYETTA and the promise of exenatide once weekly as a potential new treatment option for patients with type 2 diabetes,” stated Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. “EASD is a venue where researchers and clinical practitioners from around the world gather to discuss new developments in diabetes care. We look forward to participating in this exchange of ideas by presenting compelling data on the exenatide molecule.”

Key exenatide abstracts for EASD 2009 include:

Clinical Trial Data

Poster: Presentation #729, Sept. 30, 1:45-2:45 p.m. CEST
“Effects of Exenatide plus Rosiglitazone on Measures of Beta Cell Function and Insulin Sensitivity in Subjects with Type 2 Diabetes Previously Treated With Metformin” will be presented by Leonard Glass, M.D.

Poster: Presentation #730, Sept. 30, 1:45-2:45 p.m. CEST
“Exenatide Once Weekly Treatment Elicits Sustained Glycaemic Control and Weight Loss Over 2 Years” will be presented by Michael Trautmann, M.D.

Poster: Presentation #739, Oct. 1, 12:45-1:45 p.m. CEST
“DURATION-2: Exenatide Once Weekly Demonstrated Superior Glycemic Control and Weight Reduction Compared to Sitagliptin or Pioglitazone After 26 Weeks of Treatment” will be presented by Carol Wysham, M.D.

Poster: Presentation #795, Oct. 1, 12:45-1:45 p.m. CEST
“Changes in Adipokines in Type 2 Diabetic Patients Treated with Exenatide versus Glimepiride on Metformin Background – Results of a Prospective, Randomized Controlled Study Over 9 Months” will be presented by Baptist Gallwitz, M.D.

Safety Assessments

Oral: Presentation #6, Sept. 30, 12:15-12:30 p.m. CEST
“Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators: A Retrospective, Cohort Study” will be presented by Gary Bloomgren, M.D.

Poster: Presentation #758, Oct. 2, 12:45-1:45 p.m. CEST
“Exenatide Once Weekly Improved Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes During One Year of Treatment” will be presented by Richard Bergenstal, M.D.

Poster: Presentation #759, Oct. 2, 12:45-1:45 p.m. CEST
“Cardiovascular Safety of Exenatide BID: An Integrated-Analysis from Long-Term Controlled Clinical Trials in Subjects with Type 2 Diabetes” will be presented by Larry Shen, Ph.D.

Poster: Presentation #768, Oct. 2, 1:45-2:45 p.m. CEST
“Safety and Tolerability of Exenatide BID in Patients With Type 2 Diabetes: Integrated Analysis of 3854 Patients From 11 Comparator Controlled Clinical Trials” will be presented by Matthew Wintle, M.D.

Patient-Reported Outcomes

Poster: Abstract Presentation #745, Oct. 1, 12:45-1:45 p.m. CEST
“DURATION 2: Weight-Related Quality of Life, Psychological Well-Being, and Satisfaction with Exenatide Once Weekly Compared to Sitagliptin or Pioglitazone After 26 Weeks of Treatment” will be presented by Jennie Best, Ph.D.

Related Stories